Adherence to pegylated combination therapy in patients with chronic hepatitis C.: Importance of the trio hepatologist, general practitioner, nurse

被引:5
|
作者
Wartelle-Bladou, C. [1 ,2 ]
Rosenthal, E. [3 ]
Ratziu, V. [4 ]
De Ledinghen, V. [5 ]
Lang, J. -P. [6 ]
Poynard, T. [4 ]
机构
[1] Ctr Hosp Pays Aix, Serv Hepatogastroenterol, F-13616 Aix En Provence 1, France
[2] Reseau Sante Prov, F-13770 Venelles, France
[3] Hop Archet 1, Serv Med Interne, F-06202 Nice 3, France
[4] Hop La Pitie Salpetriere, Serv Hepatogastroenterol, F-75013 Paris, France
[5] Hop Haut Leveque, Serv Hepatogastroenterol, F-33600 Pessac, France
[6] Ctr Hosp Erstein, F-67152 Erstein, France
来源
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE | 2008年 / 32卷 / 03期
关键词
hepatitis C; compliance; general practitioner; ribavirin; peginterferon alpha-2b; peginterferon alpha-2a;
D O I
10.1016/S0399-8320(08)73272-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Adhesion to pegylated combination therapy is a key factor for therapeutic success in patients HCV infected. To optimize it, goats to reach are to limit dose reduction and premature discontinuation of treatment due to adverse events; to improve the patient compliance to treatment, particularly during the first three months, particularly to ribavirin. Therapeutic education, management of psychiatric adverse events, epoetin alfa, have demonstrated their benefit in terms of sustained virologic response or quality of life. Preparing the treatment with the patient and a multi-disciplinary team, setting successive therapeutic goals with the predictive value of the early virologic response will promote adhesion to treatment. A hepatitis C training program for general practitioners (GP) allows an efficient follow-up of treated patients by a trio hepatologist - GP -nurse and a concrete implication of GP in the field of hepatitis C. Further developments are needed for : taking in account the patient quality of life during treatment to anticipate premature discontinuation, promotion of therapeutic education by specialized nurses, standardization of the diagnosis of depression during treatment, and regular updating of general practitioners on antiviral C treatment (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S96 / S108
页数:13
相关论文
共 50 条
  • [41] Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience
    Tanioka, Daisuke
    Iwasaki, Yoshiaki
    Araki, Yasuyuki
    Osawa, Toshiya
    Ikeda, Hiroshi
    Ando, Masaharu
    Kobashi, Haruhiko
    Sakaguchi, Kohsaku
    Shiratori, Yasushi
    Yamamoto, Kazuhide
    LIVER INTERNATIONAL, 2009, 29 (05) : 721 - 729
  • [42] Tolerance to pegylated interferon maintenance therapy in patients with chronic hepatitis C who are non-responders to standard combination therapy.
    Selim, K
    Behling, C
    Lyche, KD
    Winston, DH
    Rossi, SJ
    Wahlstrom, EH
    Hyun, CB
    Jensen, JE
    Babich, MM
    Nguyen, TT
    Stewart, MA
    Myers, WY
    Ziegler, EA
    Oliver, DL
    Hassanein, TI
    HEPATOLOGY, 2002, 36 (04) : 574A - 574A
  • [43] Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C
    McHutchison, JG
    Manns, M
    Patel, K
    Poynard, T
    Lindsay, KL
    Trepo, C
    Dienstag, J
    Lee, WM
    Mak, C
    Garaud, JJ
    Albrecht, JK
    GASTROENTEROLOGY, 2002, 123 (04) : 1061 - 1069
  • [44] The clinical importance of decreasing alpha fetoprotein levels in patients with chronic hepatitis C.
    Akriviadis, EA
    Rihal, G
    Valinluck, B
    Govindarajan, S
    Redeker, AG
    HEPATOLOGY, 1997, 26 (04) : 1366 - 1366
  • [45] DOUBLE THERAPY WITH PEGYLATED INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C. A PHARMACOGENETIC GUIDE FOR PREDICTING ADVERSE EVENTS
    Kamal, Adina Maria
    Mitrut, Paul
    Docea, Anca Oana
    Sosoi, Simona Serban
    Kamal, Constantin Kamal
    Mitrut, Radu
    Margaritescu, Dragos
    Calina, Daniela
    Banciu, Cristian
    Tica, Oana Sorina
    Tica, Andrei Adrian
    Alexandru, Dragos O.
    FARMACIA, 2017, 65 (06) : 877 - 884
  • [46] Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin
    Balan, V
    Schwartz, D
    Wu, GY
    Muir, AJ
    Ghalib, R
    Jackson, J
    Keeffe, EB
    Rossaro, L
    Burnett, A
    Goon, BL
    Bowers, PJ
    Leitz, GJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (02): : 299 - 307
  • [47] Estimating the benefit of interferon therapy for individual patients with chronic hepatitis C.
    Yoshida, H
    Tateishi, R
    Arakawa, Y
    Sata, M
    Nishiguchi, S
    Ishibashi, H
    Fujiyama, S
    Yamada, G
    Yokosuka, O
    Shiratori, Y
    Omata, M
    HEPATOLOGY, 2003, 38 (04) : 641A - 641A
  • [48] Induction therapy with consensus interferon in the treatment of patients with chronic hepatitis C.
    Kwo, PY
    Fields, S
    Chalasani, N
    Cho, W
    Crabb, DW
    Cummings, OW
    Imperiale, TF
    Lumeng, L
    McGill, JM
    Ness, RM
    Pintozzi, R
    Jones, B
    Lansford, C
    Maier, J
    Isenberg, M
    Mark, D
    Bennet, C
    Noar, M
    McCone, J
    Chasen, R
    Geissinger, B
    Goldstein, M
    Thuluvath, P
    GASTROENTEROLOGY, 2000, 118 (04) : A1460 - A1460
  • [49] Influence of DAA therapy in the arterial distensibility of patients with chronic hepatitis C.
    Serejo, Fatima
    Alcantara, Paula
    Alcantara, Cristina
    Veloso, Fatima
    Moreira, Carlos
    HEPATOLOGY, 2017, 66 : 615A - 615A
  • [50] Hepatic iron concentration does not predict response to interferon/ribavirin combination therapy in patients with chronic hepatitis C.
    Hofer, H
    Steindl-Munda, P
    Kazemi-Shirazi, L
    Datz, C
    Mueller, C
    Penner, E
    Ferenci, P
    HEPATOLOGY, 1999, 30 (04) : 198A - 198A